Co-administration of molecular adjuvants expressing NF-kappa B subunit P65/RelA or type-1 transactivator T-bet enhance antigen specific DNA vaccine-induced immunity

Vaccines

Volumn 2, Issue 2, 2014, Pages 196-215

  Shedlock, Devon J ^a   Tingey, Colleen ^a   Mahadevan, Lavanya ^a   Hutnick, Natalie ^a   Reuschel, Emma L ^a   Kudchodkar, Sagar ^a   Flingai, Seleeke ^a   Yan, Jenny ^a   Kim, Joseph J ^b   Ugen, Kenneth E ^c   Weiner, David B ^a   Muthumani, Kar ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Inovio Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Adjuvant enhanced immunity; Antibody responses; DNA vaccine; T cell immunity; Transcription factors

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLASMID DNA; SYNAPTOTAGMIN I; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR T BET;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL ISOLATION; CELL PROLIFERATION ASSAY; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA TRANSFECTION; ELECTROPORATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNE RESPONSE; LUCIFERASE ASSAY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; VACCINATION; WESTERN BLOTTING;

EID: 85019428984     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2020196     Document Type: Article

References (67)

1. Zeng, Q.; Gomez, B.P.; Viscidi, R.P.; Peng, S.; He, L.; Ma, B.; Wu, T.C.; Hung, C.F. Development of a DNA vaccine targeting merkel cell polyomavirus. Vaccine 2012, 30, 1322-1329.
2. Mascola, J.R.; Montefiori, D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28, 413-444.
3. Laddy, D.J.; Yan, J.; Khan, A.S.; Andersen, H.; Cohn, A.; Greenhouse, J.; Lewis, M.; Manischewitz, J.; King, L.R.; Golding, H.; et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J. Virol. 2009, 83, 4624-4630.
4. Korber, B.; Gnanakaran, S. AIDS/HIV Converging on an HIV vaccine. Science 2011, 333, 1589-1590.
5. Zhou, T.; Georgiev, I.; Wu, X.; Yang, Z.Y.; Dai, K.; Finzi, A.; Kwon, Y.D.; Scheid, J.F.; Shi, W.; Xu, L. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329, 811-817.
6. Moir, S.; Malaspina, A.; Fauci, A.S. Prospects for an hiv vaccine: Leading B cells down the right path. Nat. Struct. Mol. Biol. 2011, 18, 1317-1321.
7. Leitner, W.W.; Baker, M.C.; Berenberg, T.L.; Lu, M.C.; Yannie, P.J.; Udey, M.C. Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen. Blood 2009, 113, 37-45.
8. Martin, J.E.; Louder, M.K.; Holman, L.A.; Gordon, I.J.; Enama, M.E.; Larkin, B.D.; Andrews, C.A.; Vogel, L.; Koup, R.A.; Roederer, M. et al. A sars DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 2008, 26, 6338-6343.
9. Shedlock, D.J.; Aviles, J.; Talbott, K.T.; Wong, G; Wu, S.J.; Villarreal, D.O.; Myles, D.J.; Croyle, M.A.; Yan, J.; Kobinger, G.P. et al. Induction of broad cytotoxic T cells by protective DNA vaccination against marburg and ebola. Mol. Ther. 2013, 21, 1432-1444.
10. Shedlock, D.J.; Silvestri, G; Weiner, D.B. Monkeying around with HIV vaccines: Using rhesus macaques to define "gatekeepers" for clinical trials. Nat. Rev. Immunol. 2009, 9, 717-728.
11. Shedlock, D.J.; Talbott, K.T.; Cress, C; Ferraro, B.; Tuyishme, S.; Mallilankaraman, K.; Cisper, N.J.; Morrow, M.P.; Wu, S.J.; Kawalekar, O.U. et al. A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine 2011, 29, 6755-6762.
12. Shedlock, D.J.; Talbott, K.T.; Wu, S.J.; Wilson, CM.; Muthumani, K.; Boyer, J.D.; Sardesai, N.Y.; Awasthi, S.; Weiner, D.B. Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. Hum. Vaccine Immunother. 2012, 8, 1668-1681.
13. Mallilankaraman, K.; Shedlock, D.J.; Bao, H.; Kawalekar, O.U.; Fagone, P.; Ramanathan, A.A.; Ferraro, B.; Stabenow, J.; Vijayachari, P.; Sundaram, S.G. et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl. Trop. Dis. 2011, 5, e928.
14. Muthumani, K.; Lankaraman, K.M.; Laddy, D.J.; Sundaram, S.G.; Chung, C.W.; Sako, E.; Wu, L.; Khan, A.; Sardesai, N.; Kim, J.J. et al. Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus. Vaccine 2008, 26, 5128-5134.
15. Bagarazzi, M.L.; Yan, J.; Morrow, M.P.; Shen, X.; Parker, R.L.; Lee, J.C.; Giffear, M.; Pankhong, P.; Khan, A.S.; Broderick, K.E. et al. Immunotherapy against HPV16/18 generates potent th1 and cytotoxic cellular immune responses. Sci. Transl. Med. 2012, 4, doi:10.1126/scitranslmed.3004414.
16. Kublin, J. Welcome to the HVTNEWS. Available online: http://www.hvtn.org/science/hvtnews/HVTNews-SpecialEdition-Sept2011-web.pdf (accessed on 1 November 2013).
17. Kutzler, M.A.; Weiner, D.B. DNA vaccines: Ready for prime time? Nat. Rev. Genet. 2008, 9, 776-788.
18. Kalams, S.A.; Parker, S.D.; Elizaga, M.; Metch, B.; Edupuganti, S.; Hural, J.; de Rosa, S.; Carter, D.K.; Rybczyk, K.; Frank, I. et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J. Infect. Dis. 2013, 208, 818-829.
19. Kee, S.T.; Gehl, J.; Lee, E.W. Clinical Aspects of Electroporation, 1st ed.; Springer: New York, NY, USA, 2011; p. 268.
20. Laddy, D.J.; Yan, J.; Kutzler, M.; Kobasa, D.; Kobinger, G.P.; Khan, A.S.; Greenhouse, J.; Sardesai, N.Y.; Draghia-Akli, R.; Weiner, D.B. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 2008, 3, e2517.
21. Yan, J.; Yoon, H.; Kumar, S.; Ramanathan, M.P.; Corbitt, N.; Kutzler, M.; Dai, A.; Boyer, J.D.; Weiner, D.B. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol. Ther. 2007, 15, 411-421.
22. Henke, A.; Chiang, C.S.; Zell, R.; Stelzner, A. Co-expression of interleukin-2 to increase the efficacy of DNA vaccine-mediated protection in coxsackievirus B3-infected mice. Antivir. Res. 2004, 64, 131-136.
23. Takahashi, S.; Yotnda, P.; Rousseau, R.F.; Mei, Z.; Smith, S.; Rill, D.; Younes, A.; Brenner, M.K. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-hodgkins lymphoma. Cancer Gene Ther. 2001, 8, 378-387.
24. Santra, S.; Barouch, D.H.; Sharpe, A.H.; Letvin, N.L. B7 co-stimulatory requirements differ for induction of immune responses by DNA, protein and recombinant pox virus vaccination. Eur. J. Immunol. 2000, 30, 2650-2659.
25. Beignon, A.S.; McKenna, K.; Skoberne, M.; Manches, O.; DaSilva, I.; Kavanagh, D.G.; Larsson, M.; Gorelick, R.J.; Lifson, J.D.; Bhardwaj, N. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via toll-like receptor-viral rna interactions. J. Clin. Invest. 2005, 115, 3265-3275.
26. +T cells. PLoS One 2010, 5, e11019.
27. +T cell deficient individuals. Vaccine 2012, 30, 2768-2777.
28. Sin, J.I. Myd88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model. Vaccine 2011, 29, 4125-4131.
29. Belisle, S.E.; Yin, J.; Shedlock, D.J.; Dai, A.; Yan, J.; Hirao, L.; Kutzler, M.A.; Lewis, M.G.; Andersen, H.; Lank, S.M. et al. Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccine. PLoS One 2011, 6, e19681.
30. Hirao, L.A.; Wu, L.; Khan, A.S.; Satishchandran, A.; Draghia-Akli, R.; Weiner, D.B. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008, 26, 440-448.
31. Fagone, P.; Shedlock, D.J.; Bao, H.; Kawalekar, O.U.; Yan, J.; Gupta, D.; Morrow, M.P.; Patel, A.; Kobinger, G.P.; Muthumani, K. et al. Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. Gene Ther. 2011, 18, 1070-1077.
32. Muthumani, G.; Laddy, D.J.; Sundaram, S.G.; Fagone, P.; Shedlock, D.J.; Kannan, S.; Wu, L.; Chung, C.W.; Lankaraman, K.M.; Burns, J. et al. Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific cd8 t cells. Immunology 2009, 128, e612-e620.
33. Kutzler, M.A.; Kraynyak, K.A.; Nagle, S.J.; Parkinson, R.M.; Zharikova, D.; Chattergoon, M.; Maguire, H.; Muthumani, K.; Ugen, K.; Weiner, D.B. Plasmids encoding the mucosal chemokines ccl27 and ccl28 are effective adjuvants in eliciting antigen-specific immunity in vivo. Gene Ther. 2010, 17, 72-82.
34. Boyer, J.D.; Robinson, T.M.; Kutzler, M.A.; Parkinson, R.; Calarota, S.A.; Sidhu, M.K.; Muthumani, K.; Lewis, M.; Pavlakis, G.; Felber, B. et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J. Med. Primatol. 2005, 34, 262-270.
35. Hirao, L.A.; Wu, L.; Khan, A.S.; Hokey, D.A.; Yan, J.; Dai, A.; Betts, M.R.; Draghia-Akli, R.; Weiner, D.B. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008, 26, 3112-3120.
36. Boyer, J.D.; Robinson, T.M.; Kutzler, M.A.; Vansant, G.; Hokey, D.A.; Kumar, S.; Parkinson, R.; Wu, L.; Sidhu, M.K.; Pavlakis, G.N. et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6 P in macaques after coimmunization with shiv antigen and IL-15 plasmid. Proc. Natl. Acad. Sci. USA 2007, 104, 18648-18653.
37. Pietila, T.E.; Veckman, V.; Lehtonen, A.; Lin, R.; Hiscott, J.; Julkunen, I. Multiple NF-κb and IFN regulatory factor family transcription factors regulate CCL19 gene expression in human monocyte-derived dendritic cells. J. Immunol. 2007, 178, 253-261.
38. Gocke, A.R.; Hussain, R.Z.; Yang, Y.; Peng, H.; Weiner, J.; Ben, L.H.; Drew, P.D.; Stuve, O.; Lovett-Racke, A.E.; Racke, M.K. Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. J. Immunol. 2009, 182, 4479-4487.
39. Gilmore, T.D.; Herscovitch, M. Inhibitors of NF-kappab signaling: 785 and counting. Oncogene 2006, 25, 6887-6899.
40. +T lymphocytes. Science 1992, 256, 1452-1456.
41. Doi, T.S.; Takahashi, T.; Taguchi, O.; Azuma, T.; Obata, Y. Nf-Kb rela-deficient lymphocytes: Normal development of T cells and B cells, impaired production of IGA and IGG1 and reduced proliferative responses. J. Exp. Med. 1997, 185, 953-961.
42. Bouwmeester, T.; Bauch, A.; Ruffner, H.; Angrand, P.O.; Bergamini, G; Croughton, K.; Cruciat, C; Eberhard, D.; Gagneur, J.; Ghidelli, S. et al. A physical and functional map of the human TNF-a/NF-Kb signal transduction pathway. Nat. Cell Biol. 2004, 6, 97-105.
43. Didonato, J.A. IKK alpha on center stage. Sci. STKE 2001, doi:10.1126/stke.2001.97.pel.
44. DiDonato, J.A.; Hayakawa, M.; Rothwarf, D.M.; Zandi, E.; Karin, M. A cytokine-responsive ikappab kinase that activates the transcription factor nf-kappab. Nature 1997, 388, 548-554.
45. DiDonato, J.A.; Mercurio, F.; Karin, M. Nf-Kb and the link between inflammation and cancer. Immunol. Rev. 2012, 246, 379-400.
46. Vallabhapurapu, S.; Karin, M. Regulation and function of NF-Kb transcription factors in the immune system. Annu. Rev. Immunol. 2009, 27, 693-733.
47. Hu, D.; Wu, J.; Zhang, R.; Chen, L. T-bet acts as a powerful adjuvant in AG85B DNA-based vaccination against tuberculosis. Mol. Med. Rep. 2012, 6, 139-144.
48. Martins, G.A.; Hutchins, A.S.; Reiner, S.L. Transcriptional activators of helper T cell fate are required for establishment but not maintenance of signature cytokine expression. J. Immunol. 2005, 175, 5981-5985.
49. Yang, J.S.; Kim, J.J.; Hwang, D.; Choo, AY.; Dang, K.; Maguire, H.; Kudchodkar, S.; Ramanathan, M.P.; Weiner, D.B. Induction of potent Thl-type immune responses from a novel DNA vaccine for west nile virus new york isolate (WNV-NY1999). J. Infect. Dis. 2001, 184, 809-816.
50. Egan, M.A.; Megati, S.; Roopchand, V.; Garcia-Hand, D.; Luckay, A.; Chong, S.Y.; Rosati, M.; Sackitey, S.; Weiner, D.B.; Felber, B.K. et al. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple hiv antigens in mice. Vaccine 2006, 24, 4510-4523.
51. Muthumani, K.; Zhang, D.; Dayes, N.S.; Hwang, D.S.; Calarota, S.A.; Choo, A.Y.; Boyer, J.D.; Weiner, D.B. Novel engineered HIV-1 east african clade-a gpl60 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology 2003, 314, 134-146.
52. Muthumani, K.; Choo, A.Y.; Zong, W.X.; Madesh, M.; Hwang, D.S.; Premkumar, A.; Thieu, K.P.; Emmanuel, J.; Kumar, S.; Thompson, C.B. et al. The HIV-1 vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat. Cell Biol. 2006, 8, 170-179.
53. Muthumani, K.; Shedlock, D.J.; Choo, D.K.; Fagone, P.; Kawalekar, O.U.; Goodman, J.; Bian, C.B.; Ramanathan, A.A.; Atman, P.; Tebas, P. et al. HTV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCS leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells. J. Immunol. 2011, 187, 2932-2943.
54. Muthumani, K.; Choo, A.Y.; Shedlock, D.J.; Laddy, D.J.; Sundaram, S.G.; Hirao, L.; Wu, L.; Thieu, K.P.; Chung, C.W.; Lankaraman, K.M. et al. Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J. Virol. 2008, 82, 11536-11544.
55. Muthumani, K. Transient transfection and luciferase assay. Protoc. Exchange 2006, doi:10.1038/nprot.2006.362.
56. Szabo, S.J.; Kim, S.T.; Costa, G.L.; Zhang, X.; Fathman, C.G.; Glimcher, L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100, 655-669.
57. Shedlock, D.J.; Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300, 337-339.
58. Hirao, L.A.; Wu, L.; Satishchandran, A.; Khan, A.S.; Draghia-Akli, R.; Finnefrock, A.C.; Bett, A.J.; Betts, M.R.; Casimiro, D.R.; Sardesai, N.Y. et al. Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant AD5 vector or plasmid DNA in rhesus macaques. Mol. Ther. 2010, 18, 1568-1576.
59. GraphPad Prism5 Software. GraphPad Software, Inc.: La Jolla, CA, USA, 2013.
60. +T cell memory recall but not effector responses. Nat. Med. 2012, 18, 422-428.
61. Jung, M.Y.; Kim, H.S.; Hong, H.J.; Youn, B.S.; Kim, T.S. Adiponectin induces dendritic cell activation via PLCGamma/JNK/NF-Kb pathways, leading to Th1 and Th17 polarization. J. Immunol. 2012, 188, 2592-2601.
62. Tas, S.W.; de Jong, E.C.; Hajji, N.; May, M.J.; Ghosh, S.; Vervoordeldonk, M.J.; Tak, P.P. Selective inhibition of NF-Kb in dendritic cells by the nemo-binding domain peptide blocks maturation and prevents T cell proliferation and polarization. Eur. J. Immunol. 2005, 35, 1164-1174.
63. Ouaaz, F.; Arron, J.; Zheng, Y.; Choi, Y.; Beg, A.A. Dendritic cell development and survival require distinct NF-Kb subunits. Immunity 2002, 16, 257-270.
64. Chen, C.C.; Rosenbloom, C.L.; Anderson, D.C.; Manning, A.M. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B-alpha phosphorylation. J. Immunol. 1995, 155, 3538-3545.
65. Wang, N.S.; McHeyzer-Williams, L.J.; Okitsu, S.L.; Burris, T.P.; Reiner, S.L.; McHeyzer-Williams, M.G. Divergent transcriptional programming of class-specific B cell memory by T-bet and roralpha. Nat. Immunol. 2012, 13, 604-611.
66. Perkins, N.D. The diverse and complex roles of NF-Kb subunits in cancer. Nat. Rev. Cancer 2012, 12, 121-132.
67. Imanifooladi, A.A.; Yazdani, S.; Nourani, M.R. The role of nuclear factor-kappab in inflammatory lung disease. Inflamm. Allergy Drug Targets 2000, 9, 197-205.